217 related articles for article (PubMed ID: 31209013)
1. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the
Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013
[TBL] [Abstract][Full Text] [Related]
2.
Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.
Misawa K; Nishimura T; Kashimura S; Enoki Y; Taguchi K; Uno S; Uwamino Y; Matsumoto K; Hasegawa N
Int J Antimicrob Agents; 2022; 60(5-6):106669. PubMed ID: 36064079
[TBL] [Abstract][Full Text] [Related]
5. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
6. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
8. Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem.
Le Run E; Atze H; Arthur M; Mainardi JL
J Antimicrob Chemother; 2020 Feb; 75(2):379-383. PubMed ID: 31637424
[TBL] [Abstract][Full Text] [Related]
9. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
11. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
[TBL] [Abstract][Full Text] [Related]
13. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
Mushtaq S; Vickers A; Woodford N; Haldimann A; Livermore DM
J Antimicrob Chemother; 2019 Apr; 74(4):953-960. PubMed ID: 30590470
[TBL] [Abstract][Full Text] [Related]
14. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
15.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
16. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.
Dousa KM; Kurz SG; Taracila MA; Bonfield T; Bethel CR; Barnes MD; Selvaraju S; Abdelhamed AM; Kreiswirth BN; Boom WH; Kasperbauer SH; Daley CL; Bonomo RA
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393499
[No Abstract] [Full Text] [Related]
17. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Kaushik A; Gupta C; Fisher S; Story-Roller E; Galanis C; Parrish N; Lamichhane G
Future Microbiol; 2017 May; 12(6):473-480. PubMed ID: 28326811
[TBL] [Abstract][Full Text] [Related]
18. The
Fröberg G; Ahmed A; Chryssanthou E; Davies Forsman L
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0052823. PubMed ID: 37671880
[TBL] [Abstract][Full Text] [Related]
19. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
20. Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.
Rajavel M; Kumar V; Nguyen H; Wyatt J; Marshall SH; Papp-Wallace KM; Deshpande P; Bhavsar S; Yeole R; Bhagwat S; Patel M; Bonomo RA; van den Akker F
mBio; 2021 Feb; 12(1):. PubMed ID: 33593978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]